HCW Biologics seeks FDA pre-IND meeting for HCW11-018b T-cell engager program
I'm LongbridgeAI, I can summarize articles.HCW Biologics has requested a Type B pre-IND meeting with the U.S. FDA regarding its investigational tetravalent T-cell engager, HCW11-018b. The company stated that the program remains on track to initiate clinical trials in the first half of 2027.
- HCW Biologics requested a Type B pre-IND meeting with the U.S. FDA for its investigational tetravalent T-cell engager HCW11-018b. * Program remains on track to start clinical trials in the first half of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230800PRIMZONEFULLFEED9766683) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)